See more : Key Energy Services, Inc. (KEGX) Income Statement Analysis – Financial Results
Complete financial analysis of Tempest Therapeutics, Inc. (TPST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tempest Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FJ Next Holdings Co., Ltd. (8935.T) Income Statement Analysis – Financial Results
- John Wood Group PLC (WG.L) Income Statement Analysis – Financial Results
- Sejal Glass Limited (SEJAL.BO) Income Statement Analysis – Financial Results
- Austin Gold Corp. (AUST) Income Statement Analysis – Financial Results
- Ramelius Resources Limited (RMLRF) Income Statement Analysis – Financial Results
Tempest Therapeutics, Inc. (TPST)
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 9.74M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -381.00K | -1.81M | -1.27M | -815.00K | -1.05M | -32.00K | 267.00K | -4.75M | -1.97M | 9.74M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.51% | -727.11% | -711.91% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.50M | 22.53M | 17.17M | 14.39M | 27.84M | 14.43M | 14.53M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M | 1.17M |
| General & Administrative | 11.66M | 12.11M | 9.82M | 4.91M | 5.51M | 12.45M | 27.74M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 16.50M | -3.79M | -21.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.66M | 12.11M | 9.82M | 4.91M | 16.50M | 8.66M | 5.93M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 1.45M |
| Other Expenses | 0.00 | 549.00K | -34.00K | 0.00 | 0.00 | 0.00 | 4.03M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 44.35M | 23.08M | 20.45M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M | 2.62M |
| Cost & Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 45.40M | 23.12M | 20.48M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M | 2.62M |
| Interest Income | 1.12M | 549.00K | 1.28K | 90.00K | 264.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.00K | 0.00 |
| Interest Expense | 1.45M | 1.62M | 1.28M | 0.00 | 0.00 | 134.00K | 0.00 | 659.00K | 436.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 2.24M | 1.29M | 450.00K | 231.00K | 0.00 | 0.00 |
| EBITDA | -28.78M | -32.28M | -25.72M | -18.39M | -43.52M | -27.01M | -84.27M | -79.82M | -71.86M | -49.07M | -28.81M | -13.53M | -2.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,933.56% | -11,236.45% | -25,528.16% | -504.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.16M | -34.64M | -26.99M | -19.30M | -45.40M | -23.12M | -20.48M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M | -2.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,943.05% | -11,579.17% | -25,992.42% | -492.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -334.00K | -1.07M | -1.32M | 90.00K | -21.19M | -4.06M | -64.10M | -1.05M | -1.15M | -1.59M | 90.00K | 19.00K | 0.00 |
| Income Before Tax | -29.49M | -35.71M | -28.30M | -19.21M | -44.57M | -27.18M | -84.59M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,673.22% | -12,566.46% | -26,405.78% | -508.68% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.07M | 1.25M | -90.00K | 1.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 0.00 | 0.00 |
| Net Income | -29.49M | -36.78M | -29.55M | -19.12M | -44.57M | -27.19M | -84.58M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M | -2.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,670.51% | -12,597.24% | -26,432.85% | -508.68% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| EPS Diluted | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| Weighted Avg Shares Out | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one...
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that members of senior management will participate in a fireside chat at...
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30, 2024, and provided a...
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics Inc. TPST stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro.
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025 The company is preparing for the Phase 3 study start in the first quarter of 2025
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two...
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one...
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and...
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended June 30, 2024, and provided a...
Source: https://incomestatements.info
Category: Stock Reports